V16 Stock Overview
Manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for V16 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Virbac SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €303.50 |
| 52 Week High | €392.00 |
| 52 Week Low | €303.50 |
| Beta | 0.97 |
| 1 Month Change | -4.71% |
| 3 Month Change | -21.88% |
| 1 Year Change | -13.90% |
| 3 Year Change | -26.96% |
| 5 Year Change | 30.54% |
| Change since IPO | 179.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| V16 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.0% | -2.2% | -2.0% |
| 1Y | -13.9% | -15.6% | 6.9% |
Return vs Industry: V16 exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: V16 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| V16 volatility | |
|---|---|
| V16 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V16 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: V16's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 5,459 | Habib Ramdani | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
| V16 fundamental statistics | |
|---|---|
| Market cap | €2.59b |
| Earnings (TTM) | €141.19m |
| Revenue (TTM) | €1.34b |
18.4x
P/E Ratio1.9x
P/S RatioIs V16 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V16 income statement (TTM) | |
|---|---|
| Revenue | €1.34b |
| Cost of Revenue | €446.54m |
| Gross Profit | €892.83m |
| Other Expenses | €751.63m |
| Earnings | €141.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 14, 2025
| Earnings per share (EPS) | 16.86 |
| Gross Margin | 66.66% |
| Net Profit Margin | 10.54% |
| Debt/Equity Ratio | 37.2% |
How did V16 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield8%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Virbac SA is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laurent Gelebart | BNP Paribas Exane |
| Carole Rozen | CA Cheuvreux |
| Arnaud Cadart | CIC Market Solutions (ESN) |